AXDX - Accelerate Diagnostics Inc Long-Term Liabilities to Capital

This price chart for Accelerate Diagnostics (AXDX) helps assess the stability of the company, which develops rapid tests for clinics where the sale of resistance diagnostic cards ensures a steady cash flow. An innovative approach to microbiology accelerates sepsis therapy selection, saving patients. However, the slow adoption of Pheno systems is leading to losses, and the liquidity deficit stands at 0.00, forcing the business to urgently seek financing.

This indicator reflects the proportion of debt with a maturity of more than one year relative to the company's equity. This metric determines the extent to which the financing structure depends on external creditors. For Accelerate Diagnostics (AXDX), expanding the diagnostic equipment supply chain requires significant investment. By analyzing the long-term financial leverage ratio, an investor assesses the business's resilience to debt obligations. An optimal balance minimizes bankruptcy risks while maintaining the potential for profitability growth.